Three “Strong-Buy” Penny Stocks – Analysts Recommend

Three “Strong-Buy” Penny Stocks – Analysts Recommend

The stock market is extensive, with so many choices. But it’s not always easy to decide where to sink money, especially if you have modest funds. Penny stocks offer an ideal solution in such cases, as they usually cost under $5 per share. But while some of them really bring great profits, others can’t manage to reach a high level and stay as they are.

Therefore, it’s very important to invest wisely. Experts study the penny stocks’ potential and recommend those futures, which have a real shot for hefty gains. Here are three stocks that may hit high this year.

Matinas BioPharma Holdings

Analysts think this stock is a good buy. The company plans to provide new treatments for cardiovascular and metabolic conditions. It is devising new medicine, which will be very effective hypertriglyceridemia treatment.

Stock’s present price is $1.35 per share. Gregg Gilbert, SunTrust Robinson analyst, noted that now is an excellent time to buy this stock. According to him, the new drug, MAT9001, could carve out a nice slice of the omega-3 market. Gilbert set the price target at $3, with a 122% gain potential over the next twelve months.

Marrone Bio Innovations

This company uses microorganisms to find effective solutions for plant health and pest management. The stock is presently trading for $1.14 per share, but experts think this price can increase soon.

Marrone Bio Innovations had some drawbacks, but it managed to overcome obstacles. It grew by 46% in the first three quarters of 2019. National Securities analyst Ben Klieve set its price target at $2.50, with 119% potential gain in the next twelve months.

TETRA Technologies

This company provides the upstream energy industry with solutions for water management and completion fluids. Furthermore, it also offers various compression services. The stock’s current price tag is $1.51 per share.

TETRA had several difficulties during 2019, but this stock still has a lot of potential for gain. Tom Curran from B.Riley FBR thinks that it can gain 132% during the next twelve months. However, he reduced the price target from $3.75 to $3.50.



  • Support
  • Platform
  • Spread
  • Trading Instrument
Comments Rating 0 (0 reviews)